$ONCT
Oncternal Therapeutics Inc

2013 Q1 Form 10-K Financial Statement

#000104746913002200 Filed on March 05, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q4 2012
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.020M $2.860M $10.85M
YoY Change 16.6% -8.92% -9.81%
% of Gross Profit
Research & Development $9.614M $10.05M $38.89M
YoY Change -2.25% 13.4% 21.76%
% of Gross Profit
Depreciation & Amortization $150.0K $150.0K $750.0K
YoY Change -28.57% -31.82% -27.88%
% of Gross Profit
Operating Expenses $12.64M $12.91M $49.73M
YoY Change 1.72% 7.54% 13.12%
Operating Profit -$12.64M -$12.91M -$49.73M
YoY Change 1.72% 7.54% 38.53%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $55.00K -$33.00K -$19.00K
YoY Change 587.5% -150.0% -104.77%
Pretax Income -$12.58M -$12.94M -$49.75M
YoY Change 1.35% 8.41% 40.14%
Income Tax $0.00 -$2.273M -$8.821M
% Of Pretax Income
Net Earnings -$12.58M -$10.72M -$27.08M
YoY Change 13.56% 0.31% -18.68%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.000M -$1.707M -$4.312M
COMMON SHARES
Basic Shares Outstanding 62.89M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q4 2012
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.20M $56.10M $56.10M
YoY Change -34.06% -24.6% -24.6%
Cash & Equivalents $36.14M $48.04M $48.00M
Short-Term Investments $6.100M $8.000M $8.000M
Other Short-Term Assets $1.400M $700.0K $700.0K
YoY Change -6.67% -46.15% -46.15%
Inventory
Prepaid Expenses
Receivables $9.000K
Other Receivables
Total Short-Term Assets $43.60M $56.82M $56.80M
YoY Change -34.44% -26.07% -26.04%
LONG-TERM ASSETS
Property, Plant & Equipment $389.0K $507.0K $500.0K
YoY Change -56.78% -53.74% -54.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.102M $959.0K $1.000M
YoY Change 0.18% -46.96% -47.37%
TOTAL ASSETS
Total Short-Term Assets $43.60M $56.82M $56.80M
Total Long-Term Assets $1.102M $959.0K $1.000M
Total Assets $44.70M $57.77M $57.80M
YoY Change -33.88% -26.55% -26.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $1.707M $1.700M
YoY Change 22.22% 40.03% 41.67%
Accrued Expenses $7.000M $7.800M $300.0K
YoY Change 48.94% 69.57% -92.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.149M $9.495M $9.500M
YoY Change 45.52% 62.78% 63.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $488.0K $578.0K $600.0K
YoY Change 144.0% -39.09% -33.33%
Total Long-Term Liabilities $488.0K $578.0K $600.0K
YoY Change 144.0% -39.09% -33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.149M $9.495M $9.500M
Total Long-Term Liabilities $488.0K $578.0K $600.0K
Total Liabilities $8.637M $10.07M $10.10M
YoY Change 48.91% 48.53% 48.53%
SHAREHOLDERS EQUITY
Retained Earnings -$425.8M -$413.2M
YoY Change 7.01%
Common Stock $461.9M $461.0M
YoY Change 0.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.06M $47.70M $47.70M
YoY Change
Total Liabilities & Shareholders Equity $44.70M $57.77M $57.80M
YoY Change -33.88% -26.55% -26.56%

Cashflow Statement

Concept 2013 Q1 2012 Q4 2012
OPERATING ACTIVITIES
Net Income -$12.58M -$10.72M -$27.08M
YoY Change 13.56% 0.31% -18.68%
Depreciation, Depletion And Amortization $150.0K $150.0K $750.0K
YoY Change -28.57% -31.82% -27.88%
Cash From Operating Activities -$13.92M -$10.07M -$37.11M
YoY Change 32.47% 17.92% 12.15%
INVESTING ACTIVITIES
Capital Expenditures $29.00K -$10.00K $142.0K
YoY Change 162.96%
Acquisitions
YoY Change
Other Investing Activities $1.960M $19.41M $21.55M
YoY Change -26.04% -2080.61% -310.24%
Cash From Investing Activities $1.931M $19.39M $21.41M
YoY Change -27.13% -2058.59% -307.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $84.00K -20.00K $3.000K
YoY Change 250.0% 0.0% -99.99%
NET CHANGE
Cash From Operating Activities -$13.92M -10.07M -$37.11M
Cash From Investing Activities $1.931M 19.39M $21.41M
Cash From Financing Activities $84.00K -20.00K $3.000K
Net Change In Cash -$11.91M 9.300M -$15.70M
YoY Change 51.97% -197.38% -382.19%
FREE CASH FLOW
Cash From Operating Activities -$13.92M -$10.07M -$37.11M
Capital Expenditures $29.00K -$10.00K $142.0K
Free Cash Flow -$13.95M -$10.06M -$37.25M
YoY Change 32.75% 17.8% 12.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62790223 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62790223 shares
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
47701000 USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62818424 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62818424 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9495000 USD
CY2012Q4 us-gaap Assets
Assets
57774000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78656000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
71874000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-386174000 USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457985000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
63000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
949000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5833000 USD
CY2011Q4 gtxi Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
4614000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1219000 USD
CY2011Q4 us-gaap Assets
Assets
78656000 USD
CY2011Q4 gtxi Intangible And Other Assets
IntangibleAndOtherAssets
712000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1096000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
76848000 USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1266000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
161000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
981000 USD
CY2011Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
10695000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63745000 USD
CY2011 gtxi Collaboration Revenue
CollaborationRevenue
8066000 USD
CY2010 gtxi Collaboration Revenue
CollaborationRevenue
56786000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.03
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.39
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57359466 shares
CY2010 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38874721 shares
CY2012 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
18831000 USD
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
298000 USD
CY2011 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
8066000 USD
CY2010 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
51786000 USD
CY2011 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1598000 USD
CY2010 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1687000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1040000 USD
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1573000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49751000 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-886000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8821000 USD
CY2012 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-40930000 USD
CY2012 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
22676000 USD
CY2011 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.60
CY2010 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.42
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.02
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
4226000 USD
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
4699000 USD
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
277000 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24000 USD
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55000 USD
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
527000 USD
CY2011 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
31938000 USD
CY2010 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
28495000 USD
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12027000 USD
CY2010 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13194000 USD
CY2011 us-gaap Operating Expenses
OperatingExpenses
43965000 USD
CY2010 us-gaap Operating Expenses
OperatingExpenses
41689000 USD
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-35899000 USD
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
15097000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
398000 USD
CY2010 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1363000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35501000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16460000 USD
CY2011 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-34615000 USD
CY2010 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
16460000 USD
CY2011 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
2207000 USD
CY2010 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-1166000 USD
CY2011 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1321000 USD
CY2010 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1166000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-33294000 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
15294000 USD
CY2012 us-gaap Operating Expenses
OperatingExpenses
49732000 USD
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-49732000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
371000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-420000 USD
CY2011 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1707000 USD
CY2010 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1634000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33089000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30527000 USD
CY2012Q4 gtxi Accrual For Product Returns
AccrualForProductReturns
1189000 USD
CY2011Q4 gtxi Accrual For Product Returns
AccrualForProductReturns
1114000 USD
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16000 USD
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000 USD
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000 USD
CY2011 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
15145000 USD
CY2010 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
8569000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10299000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8280000 USD
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48982000 USD
CY2010 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40288000 USD
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000 USD
CY2010 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000 USD
CY2011 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
85000 USD
CY2010 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
88000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48952000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40209000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5564000 USD
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17962000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15701000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10669000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40219000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58181000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48044000 USD
CY2012Q3 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
21671000 USD
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Use of Estimates</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual amounts and results could differ from those estimates.</font></p></div>
CY2012Q4 gtxi Accrual For Product Returns Included In Other Long Term Liabilities
AccrualForProductReturnsIncludedInOtherLongTermLiabilities
370000 USD
CY2011Q4 gtxi Accrual For Product Returns Included In Other Long Term Liabilities
AccrualForProductReturnsIncludedInOtherLongTermLiabilities
715000 USD
CY2010 us-gaap Revenue From Grants
RevenueFromGrants
1220000 USD
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5574915 shares
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5327752 shares
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Concentration of Risk</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company has established guidelines relating to diversification and maturities of its cash equivalents and short-term investments which are designed to manage risk. The Company's cash and cash equivalents consist of bank deposits, certificates of deposit, and money market mutual funds. Bank deposits may at times be in excess of FDIC insurance limits. The Company's short-term investments consist of FDIC insured certificates of deposit with original maturities of greater than three months and less than one year.</font></p></div>
CY2012 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>FARESTON</i></b></font><font size="2">&#174;</font><font size="2"><b><i>Revenue Recognition</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Revenue from product sales of FARESTON&#174;, which is included in income from discontinued operations before income taxes, was recognized less deductions for estimated sales discounts and sales returns. Revenue from product sales was recognized when persuasive evidence of an arrangement existed, title passed, the price was fixed or determinable, and collectability was reasonably assured. The Company accounted for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product's labeled expiration date. Although the Company sold its rights and certain assets related to FARESTON&#174; effective September&#160;30, 2012, the Company retains the liability for future product returns relating to sales of FARESTON&#174; made by the Company prior to September&#160;30, 2012. Therefore, the Company estimates an accrual for product returns based on factors which include historical product returns and estimated product in the distribution channel which is expected to exceed its expiration date. At December&#160;31, 2012 and December&#160;31, 2011, the Company's accrual for product returns, was $1,189 and $1,114, respectively. Of these amounts, $370 and $715 have been included in "Other long-term liabilities" in the balance sheet at December&#160;31, 2012 and December&#160;31, 2011, respectively, and represents the portion of the Company's product returns accrual estimated to be payable after one year. See Note&#160;4,</font> <font size="2"><i>Discontinued Operations</i></font><font size="2">, for further discussion.</font></p></div>
CY2012 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Collaboration Revenue Recognition</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Collaboration revenue consisted of non-refundable upfront payments, license fees, reimbursements for research and development activities, and milestone payments associated with the Company's former collaboration and license agreements. Revenues from the Company's prior collaboration and license agreements were recognized based on the performance requirements of the specific agreements. The Company analyzed agreements with multiple element arrangements to determine whether the deliverables under the agreement, including license and performance obligations such as joint steering committee participation and research and development activities, could have been separated or whether all of the deliverables must have been accounted for as a single unit of accounting. See Note&#160;8,</font> <font size="2"><i>Collaboration and License Agreements</i></font><font size="2">, for further discussion.</font></p></div>
CY2012 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 item
CY2012 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b><i>Reclassification</i></b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain prior period amounts have been reclassified to conform to the current period discontinued operations presentation. See note&#160;4, Discontinued Operations, for further discussion. Additionally, in the balance sheet at December&#160;31, 2011, the Company has included $472 of current deferred income tax liabilities, which were previously reported net of noncurrent deferred income tax assets, in accrued expenses and other current liabilities, which is consistent with the current year balance sheet presentation.</font></p></div>
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4473576 shares
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2817000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4404000 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4886000 USD
CY2011 gtxi Share Based Compensation Arrangement By Share Based Payment Award Reversal Of Previously Recognized Share Based Compensation Expense For Nonvested Stock Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardReversalOfPreviouslyRecognizedShareBasedCompensationExpenseForNonvestedStockOptions
704000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.62
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.696 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.649 pure
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.646 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0122 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0254 pure
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0336 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2011 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2010 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y6M
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2009Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3364871 shares
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4430495 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4945565 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5382859 shares
CY2009Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.55
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.91
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.12
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.96
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1320500 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1395000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1141250 shares
CY2010 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.14
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.82
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.35
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
250626 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
866930 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
675755 shares
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.68
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.23
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.82
CY2010 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.24
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.20
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.05
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5239584 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.07
CY2012Q4 gtxi Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
5621000 USD
CY2012Q4 gtxi Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
730000 USD
CY2012Q4 gtxi Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
46000 USD
CY2012Q4 gtxi Capital Lease Obligations And Financed Equipment Liabilities Current
CapitalLeaseObligationsAndFinancedEquipmentLiabilitiesCurrent
7000 USD
CY2011Q4 gtxi Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2286000 USD
CY2011Q4 gtxi Accrued Selling General And Administrative Expense Current
AccruedSellingGeneralAndAdministrativeExpenseCurrent
1037000 USD
CY2011Q4 gtxi Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
73000 USD
CY2011Q4 gtxi Capital Lease Obligations And Financed Equipment Liabilities Current
CapitalLeaseObligationsAndFinancedEquipmentLiabilitiesCurrent
82000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9268000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9204000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8761000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8108000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
507000 USD
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2359000 USD
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M13D
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
421000 USD
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1508000 USD
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y9M11D
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2233000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
36000 USD
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15000 USD
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000 USD
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4211000 USD
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M29D
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4573224 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4648224 shares
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
963000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
933000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1200000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1348000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
185000 USD
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2733000 USD
CY2012Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
331000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8852000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
131543000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9799000 USD
CY2011Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1334000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8307000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
122707000 USD
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8836000 USD
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13218000 USD
CY2010 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-3878000 USD
CY2012Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9835000 USD
CY2012Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9237000 USD
CY2012Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9764000 USD
CY2012Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10051000 USD
CY2011Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7303000 USD
CY2011Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7591000 USD
CY2011Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8181000 USD
CY2011Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8863000 USD
CY2011Q1 gtxi Collaboration Revenue
CollaborationRevenue
8066000 USD
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2588000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2400000 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2999000 USD
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2858000 USD
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3201000 USD
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2977000 USD
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2708000 USD
CY2011Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3141000 USD
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
12423000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
11637000 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
12763000 USD
CY2011Q1 us-gaap Operating Expenses
OperatingExpenses
10504000 USD
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
10568000 USD
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
10889000 USD
CY2011Q4 us-gaap Operating Expenses
OperatingExpenses
12004000 USD
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12423000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11637000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12763000 USD
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2438000 USD
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10568000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10889000 USD
CY2011Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12004000 USD
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47000 USD
CY2011Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
302000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000 USD
CY2011Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 USD
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000 USD
CY2011Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
66000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12415000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11584000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12810000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2136000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10561000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10866000 USD
CY2011Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11938000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5812000 USD
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-271000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12034000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11229000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6998000 USD
CY2011Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2083000 USD
CY2011Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10297000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10595000 USD
CY2011Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11640000 USD
CY2012Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1335000 USD
CY2012Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1203000 USD
CY2012Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
20214000 USD
CY2012Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-76000 USD
CY2011Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-459000 USD
CY2011Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-112000 USD
CY2011Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1522000 USD
CY2011Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
1256000 USD
CY2012Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
8115000 USD
CY2012Q4 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
-30000 USD
CY2011Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
271000 USD
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2012Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
954000 USD
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
848000 USD
CY2012Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
12099000 USD
CY2011Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-512000 USD
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-376000 USD
CY2011Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
1251000 USD
CY2011Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
958000 USD
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-11080000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-10381000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
5101000 USD
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-2595000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-10673000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-9344000 USD
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
-10682000 USD
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.19
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.11
CY2012Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2011Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.04
CY2011Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.20
CY2011Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.17
CY2011Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.19
CY2012Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.01
CY2012Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.01
CY2012Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.19
CY2011Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.01
CY2011Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
-0.01
CY2011Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.02
CY2011Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.02
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.08
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62798008 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62805662 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62815549 shares
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62817495 shares
CY2011Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51719187 shares
CY2011Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51968667 shares
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62778575 shares
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62790223 shares
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
750000 USD
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
12909000 USD
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12909000 USD
CY2012Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000 USD
CY2012Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12942000 USD
CY2012Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2273000 USD
CY2012Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-46000 USD
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-10715000 USD
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
112233000 USD
CY2012 gtxi Defined Contribution Plan Maximum Annual Contribution Per Employee Who Is Under Specified Age In Current Calendar Year
DefinedContributionPlanMaximumAnnualContributionPerEmployeeWhoIsUnderSpecifiedAgeInCurrentCalendarYear
17000 USD
CY2012Q4 gtxi Defined Contribution Plan Specified Age For Current Calendar Year To Determine Employee Contribution
DefinedContributionPlanSpecifiedAgeForCurrentCalendarYearToDetermineEmployeeContribution
50 item
CY2012 gtxi Defined Contribution Plan Maximum Annual Contribution Per Employee Who Is Equal To And Older Than Specified Age In Current Calendar Year
DefinedContributionPlanMaximumAnnualContributionPerEmployeeWhoIsEqualToAndOlderThanSpecifiedAgeInCurrentCalendarYear
22500 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
101777000 USD
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
-8750000 USD
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
40288000 USD
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000 USD
CY2010 gtxi Directors Deferred Compensation
DirectorsDeferredCompensation
187000 USD
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4699000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
51727000 USD
CY2011 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48982000 USD
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000 USD
CY2011 gtxi Directors Deferred Compensation
DirectorsDeferredCompensation
178000 USD
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4226000 USD
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2648000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
2648000 USD
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-972000 USD
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000 USD
CY2012 gtxi Directors Deferred Compensation
DirectorsDeferredCompensation
169000 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
GTX INC /DE/
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001260990
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q2 dei Entity Public Float
EntityPublicFloat
94929673 USD
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62891791 shares
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div style='font-size:10.0pt;FONT-FAMILY: Times New Roman;'> <p style="FONT-FAMILY: times"><font size="2"><b>1.&#160;&#160;&#160;&#160;&#160;Business</b></font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;GTx,&#160;Inc. ("GTx" or the "Company"), a Delaware corporation incorporated on September&#160;24, 1997 and headquartered in Memphis, Tennessee, is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is developing selective androgen receptor modulators ("SARMs"), including enobosarm (also known as Ostarine&#174; or GTx-024). SARMs&#160;are a new class of drugs with the potential to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). The Company is conducting two fully enrolled pivotal Phase&#160;III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additionally, the Company is developing Capesaris&#174; (GTx-758), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy. Based upon feedback from the FDA, the Company initiated in the third quarter of 2012 a Phase&#160;II clinical trial to evaluate the safety and efficacy of lower doses of Capesaris&#174; as secondary hormonal therapy in men with metastatic castration resistant prostate cancer.</font></p> <p style="FONT-FAMILY: times"><font size="2">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effective September&#160;30, 2012, the Company sold its rights and certain assets related to FARESTON&#174; to Strakan International S.&#225; r.l., an affiliate of ProStrakan Group&#160;plc ("ProStrakan") for $21,671 in cash. Through September&#160;30, 2012, the Company sold FARESTON&#174; (toremifene citrate) 60 mg tablets, approved for the treatment of metastatic breast cancer in postmenopausal women, in the United States. See Note&#160;4,</font> <font size="2"><i>Discontinued Operations</i></font><font size="2">, for further discussion.</font></p></div>
CY2012Q4 gtxi Accrued And Other Current Liabilities
AccruedAndOtherCurrentLiabilities
7788000 USD
CY2012 gtxi Share Based Compensation Arrangements By Share Based Payment Award Options Expiration Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm
P10Y
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10921000 USD
CY2011Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
264000 USD
CY2011Q4 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
298000 USD
CY2012Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8045000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
717000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
56815000 USD
CY2012Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5382859 shares
CY2012 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y10M6D
CY2012Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.96
CY2012Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2657270 shares
CY2012Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
10.32
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-381000 USD
CY2012Q4 gtxi Intangible And Other Assets
IntangibleAndOtherAssets
452000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1707000 USD
CY2010 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-189000 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-133000 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-355000 USD
CY2012Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
381000 USD
CY2012Q2 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
355000 USD
CY2011Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-53000 USD
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-264000 USD
CY2011Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-298000 USD
CY2011Q1 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
53000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
578000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
63000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
460887000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-413249000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57774000 USD
CY2012 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
38887000 USD
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10845000 USD
CY2011 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
886000 USD
CY2012 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
8821000 USD
CY2012 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
13855000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-27075000 USD
CY2012 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.65
CY2012 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
0.22
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62809219 shares
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-752000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
488000 USD
CY2012 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2885000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37109000 USD
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
142000 USD
CY2012 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11980000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21405000 USD
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85000 USD
CY2012 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
82000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 USD
CY2010 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4250 shares
CY2011 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
13000 shares
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28201 shares
CY2011Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
472000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
271000 USD
CY2012 gtxi Tax Credit Carryforward Increase Amount Research And Development
TaxCreditCarryforwardIncreaseAmountResearchAndDevelopment
1319000 USD
CY2012Q4 gtxi Tax Credit Carryforward Increase Decrease Amount Research And Development
TaxCreditCarryforwardIncreaseDecreaseAmountResearchAndDevelopment
-1122000 USD

Files In Submission

Name View Source Status
0001047469-13-002200-index-headers.html Edgar Link pending
0001047469-13-002200-index.html Edgar Link pending
0001047469-13-002200.txt Edgar Link pending
0001047469-13-002200-xbrl.zip Edgar Link pending
a2213185z10-k.htm Edgar Link pending
a2213185zex-10_19.htm Edgar Link pending
a2213185zex-10_20.htm Edgar Link pending
a2213185zex-10_21.htm Edgar Link pending
a2213185zex-10_22.htm Edgar Link pending
a2213185zex-10_23.htm Edgar Link pending
a2213185zex-10_26.htm Edgar Link pending
a2213185zex-10_28.htm Edgar Link pending
a2213185zex-10_30.htm Edgar Link pending
a2213185zex-23_1.htm Edgar Link pending
a2213185zex-31_1.htm Edgar Link pending
a2213185zex-31_2.htm Edgar Link pending
a2213185zex-32_1.htm Edgar Link pending
a2213185zex-32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g279458.jpg Edgar Link pending
gtxi-20121231.xml Edgar Link completed
gtxi-20121231.xsd Edgar Link pending
gtxi-20121231_cal.xml Edgar Link unprocessable
gtxi-20121231_def.xml Edgar Link unprocessable
gtxi-20121231_lab.xml Edgar Link unprocessable
gtxi-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending